Kisho is an information platform, not a medical provider. Nothing on this site constitutes medical advice, diagnosis, or treatment recommendations. All content is aggregated from publicly available sources (including ClinicalTrials.gov, PubMed, FDA.gov, and Orphanet) and is provided for informational purposes only. Clinical trial eligibility, treatment decisions, and any health-related actions should always be discussed with a qualified healthcare professional. Kisho does not endorse any specific therapy, organization, or clinical trial. Terms of use · Privacy policy
Any classic complement early component deficiency in which the cause of the disease is a mutation in the C6 gene.
Features include always present findings: Reduced circulating CH50 activity and Decreased circulating complement C6 concentration; and common findings: Recurrent meningococcal disease.
C6 encodes complement C6 (934 aa). Component of the membrane attack complex (MAC), a multiprotein complex activated by the complement cascade, which inserts into a target cell membrane and forms a pore, leading to target cell membrane rupture and cell lysis. Highest expression in Liver (136.2 TPM) and Heart Atrial Appendage (37.5 TPM).
Complement component 6 deficiency is associated with mutations in the C6 gene on chromosome 5.
The C6 protein participates in Deamination at C6 position of adenosine in Editosome (ADAR2), Deamination at C6 position of adenosine in Editosome (ADAR1), and HS6STs sulfate GlcN at C6 in heparan sulfate/heparin pathways.
C6 is classified as a druggable target (Druggable Genome and Transporter categories) with score 0.6.
Genetic testing for C6 is available. Testing is considered confirmatory for diagnosis.
Phenotype severity distribution: 2 always present features, 1 common feature.
No clinical trials have been registered for complement component 6 deficiency.
5 publications have been identified in PubMed for complement component 6 deficiency. Research spans Basic Science / Preclinical (60%), Review / Meta-Analysis (20%), and Case Report / Case Series (20%).
Martinez T (2026). [PMID: 41980333](https://pubmed.ncbi.nlm.nih.gov/41980333/). *Curr Opin Immunol*. [Review / Meta-Analysis]
Hao Y (2025). [PMID: 40976050](https://pubmed.ncbi.nlm.nih.gov/40976050/). *International immunopharmacology*. [Basic Science / Preclinical]
Kamiya T (2025). [PMID: 41248559](https://pubmed.ncbi.nlm.nih.gov/41248559/). *Immunobiology*. [Basic Science / Preclinical]
Zheng Y (2024). [PMID: 39823049](https://pubmed.ncbi.nlm.nih.gov/39823049/). *Open medicine (Warsaw, Poland)*. [Case Report / Case Series]
Kuhn A (2024). [PMID: 39200157](https://pubmed.ncbi.nlm.nih.gov/39200157/). *Biomedicines*. [Basic Science / Preclinical]
Data assembled from 5 of 12 sources · Last updated Sep 19, 2026, 10:41 PM UTC
Online Mendelian Inheritance in Man
Genetic and Rare Diseases Info Center
Common questions about complement component 6 deficiency